keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TAS6417 是一种高效的、具有口服活性的 EGFR 突变型抑制剂,可独特的结合到 EGFR 铰链区的 ATP 结合位点,其 IC50值为 1.1-8.0 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 923 | 现货 | ||
2 mg | ¥ 1,290 | 现货 | ||
5 mg | ¥ 1,980 | 现货 | ||
10 mg | ¥ 3,320 | 现货 | ||
25 mg | ¥ 6,660 | 现货 | ||
50 mg | ¥ 8,970 | 现货 | ||
100 mg | ¥ 11,900 | 现货 | ||
500 mg | ¥ 24,200 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,280 | 现货 |
产品描述 | TAS6417 is an EGFR inhibitor and is an efficacious drug candidate for patients with NSCLC (IC50: ranging from 1.1-8.0 nM). |
靶点活性 | EGFR:1.1-8.0 nM |
体外活性 | TAS6417 inhibits the growth of cells expressing exon 20 insertion mutations of the EGFR gene (GI50 value of 86.5±28.5 nM for LXF 2478L cells and 45.4±2.6 nM for NCI-H1975 EGFR D770_N771insSVD cells). TAS6417 also potently inhibits proliferation in other cell lines harboring activating mutations or acquired resistance mutations (mean GI50: 1.92±0.21 nM to 7.12±0.60 nM) [1]. |
体内活性 | TAS6417 inhibits mutant EGFR in tumors but not WT EGFR in skin tissues. TAS6417 induces persistent tumor regression in vivo in EGFR exon 20 insertion-driven tumor models [1]. |
分子量 | 396.44 |
分子式 | C23H20N6O |
CAS No. | 1661854-97-2 |
keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (315.31 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5224 mL | 12.6122 mL | 25.2245 mL | 63.0612 mL |
5 mM | 0.5045 mL | 2.5224 mL | 5.0449 mL | 12.6122 mL | |
10 mM | 0.2522 mL | 1.2612 mL | 2.5224 mL | 6.3061 mL | |
20 mM | 0.1261 mL | 0.6306 mL | 1.2612 mL | 3.1531 mL | |
50 mM | 0.0504 mL | 0.2522 mL | 0.5045 mL | 1.2612 mL | |
100 mM | 0.0252 mL | 0.1261 mL | 0.2522 mL | 0.6306 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
TAS6417 1661854-97-2 Angiogenesis Apoptosis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR ErbB-1 TAS-6417 PC-9 lung Inhibitor CLN081 BEAS-2B CLN 081 cancer BID007 CLN-081 inhibit NSCLC H1975 Epidermal growth factor receptor BID019 HER1 Akt TAS 6417 inhibitor